IMMUNE cell gene therapy startup Gracell Biotechnologies has raised US$85 million through a Series B round led by Singapore government investment firm Temasek Holdings.To continue reading.
IMMUNE cell gene therapy startup Gracell Biotechnologies has raised US$85 million through a Series B round led by Singapore government investment firm Temasek Holdings.To continue readingこのニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む: